Introduction
The scientific study of psychedelic substances, particularly psilocybin, the primary psychoactive compound in so-called “magic mushrooms,” has seen a significant resurgence in recent years. As research explores its potential applications in clinical settings, public interest has grown, leading to a proliferation of information across media and online platforms. However, this information is often oversimplified, creating a landscape of misinformation and public confusion. A nuanced and evidence-based discussion of the potential risks and side effects is therefore essential for public health and safety. This article aims to provide a comprehensive overview of the documented side effects, identified risks, and current understanding of the long-term effects of psychedelic mushrooms, based exclusively on findings from scientific research. It is crucial to emphasize that this article summarizes research findings only and does not provide any form of medical advice or guidance. The information presented here is intended to inform and caution, not to reassure or promote any particular use of these substances.
[Internal link: Psychedelic Mushrooms: A Science-First Overview]
Commonly Reported Side Effects in Research Settings
Clinical research on psilocybin is conducted under strictly controlled conditions, which include comprehensive medical and psychological screening of participants, administration of a known and precise dose, and continuous monitoring by trained professionals. The side effects observed in these settings are well-documented and provide valuable insight into the acute effects of psilocybin. A 2024 meta-analysis of six randomized, double-blind clinical trials involving 528 patients, published in JAMA Network Open, found that the most commonly reported adverse effects included headaches, nausea, anxiety, dizziness, and fluctuations in blood pressure [1]. These effects were generally reported as mild to moderate in intensity and typically resolved within 48 hours [1].
Specifically, the meta-analysis by Yerubandi et al. (2024) reported the following relative risk (RR) for common side effects when comparing psilocybin to a placebo or other comparator:
Side Effect | Relative Risk (RR) | 95% Confidence Interval (CI) |
Nausea | 8.85 | 5.68-13.79 |
Dizziness | 5.81 | 1.02-33.03 |
Elevated Blood Pressure | 2.29 | 1.15-4.53 |
Anxiety | 2.27 | 1.11-4.64 |
Headache | 1.99 | 1.06-3.74 |
Source: Yerubandi et al., 2024 [1]
Other physical side effects noted in research include fatigue and transient increases in heart rate (tachycardia) [4]. A study by Straumann et al. (2024) observed tachycardia in 7% of participants, describing it as a mild sympathomimetic activation [27]. It is important to reiterate that these findings are from controlled research environments with extensive participant screening. The presence of trained medical staff allows for the management of these side effects, a safety measure not available in uncontrolled settings.
[Internal link: How Psychedelic Mushrooms Affect the Brain]
Psychological Effects and Hallucinations: A Scientific Definition
In a clinical context, the term “hallucination” refers to a sensory perception that has the compelling sense of reality of a true perception but that occurs without external stimulation of the relevant sensory organ. Research literature on psilocybin often describes these phenomena as alterations in perception rather than the culturally-loaded term “hallucination.” These perceptual changes can manifest across various sensory modalities, including visual, auditory, and tactile sensations. For instance, studies may refer to “visual perceptual effects” or “distorted sights and sounds” [15] [12].
Scientific descriptions of these experiences are typically neutral and observational, focusing on the nature of the perceptual changes rather than their subjective content. For example, research might document changes in the perception of colors, patterns, and the shape of objects, or the experience of sounds being distorted. These effects are understood to be a direct result of psilocybin’s interaction with serotonin receptors in the brain, particularly the 5-HT2A receptor, which is densely expressed in regions involved in sensory processing [8]. By avoiding sensationalism and focusing on the neurobiological mechanisms, researchers aim to understand the effects of psilocybin on the brain in a rigorous and objective manner.
[Internal link: Glossary: Key Terms in Psychedelic Science]
Negative Effects and Adverse Reactions
While some media portrayals of psychedelic experiences focus on positive or transformative aspects, the scientific literature documents a significant risk of negative and adverse psychological reactions. These are often referred to in research as “challenging experiences” or, more colloquially, “bad trips.” These experiences can include intense anxiety, fear, panic, confusion, and acute psychological discomfort [34] [41]. A survey study of nearly 2,000 individuals who reported having a “bad trip” on psilocybin mushrooms highlighted the potential for significant psychological distress [42].
The variability of individual responses to psilocybin is a critical factor. A 2021 study by Gashi et al. noted that challenging experiences are common among users of psychedelics [35]. The content and intensity of these experiences are highly dependent on a range of factors, including the individual’s psychological state, personality, and the environment in which the substance is used—a concept known as “set and setting” [30]. A 2024 study by Harari et al. found that challenging experiences during psilocybin treatment were negatively correlated with antidepressant effects, suggesting that these difficult experiences can impact therapeutic outcomes [39].
Research has also documented instances of prolonged anxiety, panic, and the emergence of past traumas during psychedelic experiences [38]. A study by Kopra et al. (2022) analyzing adverse experiences that led to emergency medical treatment found that even moderate doses of psilocybin can induce reactions characterized by significant anxiety [37]. Furthermore, a study by Carbonaro et al. (2016) found that a significant percentage of individuals who had a challenging experience reported enduring negative consequences, with 24% experiencing symptoms such as anxiety, paranoia, or depression that lasted for a year or more [34] [36]. These findings underscore the importance of acknowledging and understanding the potential for acute and lasting psychological distress as a significant risk associated with psilocybin use.
Long-Term Effects — What Is Known and What Is Not
The question of long-term effects of psilocybin is a critical area of research, but one that is characterized by significant data gaps and limitations. While some studies have conducted follow-ups with participants, the duration of these follow-ups is often limited, making it difficult to draw definitive conclusions about the effects of psilocybin over a lifetime. A 2020 systematic review by Aday et al. noted that while some studies report enduring positive changes in personality, attitudes, and well-being, the evidence base is still emerging [9].
Conversely, there is also a growing body of research investigating potential long-term negative psychological outcomes. A 2023 case analysis by Bremler et al. specifically focused on negative psychological responses lasting longer than 72 hours after psychedelic use, corroborating the reality of mental health iatrogenesis in some cases [11]. Another longitudinal study by Simonsson et al. (2025) suggested that naturalistic psychedelic use, particularly in illegal contexts, may be associated with an increase in the severity of psychotic and manic symptoms over time [12]. A case report by Perna et al. (2025) detailed the experience of a psychologist who developed prolonged adverse effects, including severe sleep disturbances, after repeated high doses of psilocybin [13].
It is crucial to recognize that the current body of research does not allow for population-level conclusions about the long-term safety of psilocybin. The existing studies are often small in scale, and their findings cannot be generalized to the broader population. The lack of long-term, large-scale epidemiological studies means that many questions about the potential for rare but serious long-term effects remain unanswered. Therefore, any discussion of long-term effects must be approached with significant caution and a clear acknowledgment of the current limitations of the scientific evidence.
Risk Factors Identified in Research
Clinical trials investigating psilocybin implement rigorous screening protocols to minimize risks to participants. These protocols include a comprehensive set of exclusion criteria, which are designed to identify individuals who may be at a higher risk of experiencing adverse effects. These exclusion criteria provide valuable insight into the risk factors that have been identified in the scientific literature. It is essential to understand that this information is presented in the context of research screening and should not be interpreted as guidance for personal use.
A primary area of concern is the potential for psilocybin to trigger or exacerbate psychotic disorders. Consequently, a personal or family history of psychosis, such as schizophrenia or schizoaffective disorder, is a standard exclusion criterion in clinical trials [22]. Research has suggested a potential link between psychedelic use and an increased risk of psychosis, particularly in vulnerable individuals. A 2024 study from ICES found that individuals with emergency department visits involving hallucinogens had a significantly higher risk of a subsequent schizophrenia diagnosis [19]. Similarly, a longitudinal study by Honk et al. (2024) indicated that psychedelic use might affect psychotic symptoms in individuals with a personal or family history of certain disorders [20]. While a 2025 review by Sabé et al. noted that there is limited meta-analytic data on the risk of psychedelic-induced psychosis in individuals with pre-existing psychotic disorders, the potential risk is taken very seriously in research settings [17].
Another significant risk factor is a personal or family history of bipolar disorder. As noted by Downey et al. (2024), most modern clinical trials of psilocybin have excluded individuals with a family history of bipolar disorder due to concerns that psilocybin could trigger manic episodes [21]. In addition to psychiatric conditions, research has also identified cardiovascular health as an important consideration. Given that psilocybin can cause transient increases in blood pressure and heart rate, individuals with pre-existing heart conditions are often excluded from clinical trials [25] [33]. A 2025 publication by Williams et al. highlights that trials of psychedelic therapies have historically excluded potential participants with a range of chronic conditions that are considered to put them at higher risk [23].
[Internal link: Contraindications & Interactions Hub]
Distinguishing Research Context From Real-World Use
It is of paramount importance to understand that the findings from clinical research on psilocybin cannot be directly generalized to real-world, uncontrolled use. The conditions under which psilocybin is administered in a research setting are fundamentally different from those in any other context. These differences are critical for understanding the safety profile of psilocybin and the potential for adverse effects.
As previously mentioned, clinical trials employ a multi-layered safety framework that includes:
•Comprehensive Screening: Participants undergo extensive medical and psychological evaluations to exclude individuals with pre-existing conditions that could increase their risk of adverse reactions.
•Known and Precise Dosing: The psilocybin used in research is of a known purity and is administered in a precise, measured dose. This is in stark contrast to illicitly obtained substances, where the dosage and purity are unknown and can vary widely.
•Supportive and Monitored Environment: The administration of psilocybin in a clinical trial takes place in a carefully controlled and supportive environment, with trained therapists or medical professionals present to provide psychological support and manage any adverse reactions that may arise.
These controlled conditions are designed to maximize safety and minimize risk. In uncontrolled settings, none of these safety measures are typically in place. The absence of screening, the uncertainty of dosage and purity, and the lack of professional support create a significantly higher risk profile. Therefore, the relatively low incidence of serious adverse events reported in clinical trials should not be interpreted as an indication of the safety of psilocybin in non-clinical contexts. The extrapolation of research findings to real-world use is not only scientifically invalid but also potentially dangerous.
Red-Flag Reactions and Medical Emergencies (High-Level)
The scientific literature identifies several categories of reactions to psilocybin that are considered serious and may constitute a medical emergency. This information is provided for educational safety awareness and is not intended to be diagnostic or advisory. Any individual experiencing a medical emergency should seek immediate professional medical help.
One of the most significant concerns is the potential for a hypertensive crisis, a severe and rapid increase in blood pressure that can lead to a stroke. A 2025 report from the Cleveland Clinic highlighted a case of hypertensive emergency linked to the use of psilocybin mushrooms in a patient also taking an MAOI and amphetamine, underscoring the potential dangers of combining psilocybin with other substances [30]. Cardiovascular complications, while rare, can be severe. Research from Massachusetts General Hospital (2025) has linked high-dose psilocybin to QT prolongation, cardiac arrest, ventricular dysfunction, and myocardial infarction [6].
Another red-flag reaction is the development of psychosis. While prolonged psychosis is considered very rare in the general population, it is an incredibly dangerous potential side effect [24]. A case report by Morris et al. (2024) documented a case of psilocybin-induced psychosis, and other research has pointed to an increased risk of schizophrenia in individuals who have had emergency department visits involving hallucinogens [18] [19]. The development of severe, unmanageable anxiety, panic attacks, or paranoia can also constitute a psychological emergency that requires professional intervention [41].
Why Accurate Risk Information Matters
The increasing public and media interest in psychedelics has led to a corresponding increase in the amount of information available. However, not all of this information is accurate or balanced. Media oversimplification and social media distortion can create a skewed perception of the risks and benefits of psilocybin, often downplaying the potential for harm. This misinformation can have serious consequences, as individuals may make decisions about using these substances without a full understanding of the potential risks involved.
An evidence-based discussion of the risks associated with psilocybin is crucial for public health and safety. By focusing on the findings of scientific research, we can move beyond anecdotal reports and sensationalism to a more nuanced and accurate understanding of the potential for adverse effects. This is not to dismiss the potential therapeutic benefits that are being investigated, but rather to emphasize that a comprehensive understanding of any substance must include a thorough examination of its risks. Responsible and accurate science communication is essential to ensure that the public is well-informed and that the conversation around psychedelics is grounded in scientific evidence.
Conclusion
The scientific literature provides a clear picture of the potential side effects and risks associated with psilocybin, the active compound in psychedelic mushrooms. Research conducted in controlled clinical settings has documented a range of acute side effects, including headaches, nausea, anxiety, and transient increases in blood pressure and heart rate. While these are often manageable in a monitored environment, they underscore the physiological and psychological impact of the substance. Furthermore, the potential for challenging experiences, or “bad trips,” characterized by intense fear, paranoia, and psychological distress, represents a significant risk, particularly in uncontrolled settings.
The long-term effects of psilocybin remain an area of active research with significant uncertainties. While some studies suggest the potential for lasting positive changes, others highlight the risk of prolonged negative psychological outcomes, including the exacerbation of existing mental health conditions or the emergence of new ones. The limitations of the current research, including small sample sizes and limited long-term follow-up, make it impossible to draw definitive conclusions about the long-term safety of psilocybin.
It is critical to interpret the findings of scientific research with caution and to recognize the significant differences between controlled clinical trials and real-world use. The safety measures implemented in research settings are not present in uncontrolled environments, where the risks are substantially higher. This article has aimed to provide a balanced and evidence-based overview of the risks associated with psilocybin, as documented in the scientific literature, to promote a more informed and responsible public discourse.
Sources & Further Reading
1.Yerubandi, A., Thomas, J. E., Bhuiya, N. M. M. A., Harrington, C., Zapata, L. V., & Caballero, J. (2024). Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. JAMA Network Open, 7(4), e245960. (source)
2.Hinkle, J. T., Graziosi, M., Nayak, S. M., & Yaden, D. B. (2024). Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis. JAMA Psychiatry, 81(12), 1225–1235. (source)
3.Freitas, R. R. (2024). The safety of psilocybin-assisted psychotherapy. PubMed, 39670342. (source)
4.Bukovsky, D. (2025). Adverse event reporting and management in psilocybin. ScienceDirect. (source)
5.Perna, J., Trop, R., Palitsky, R., Bosshardt, Z., Vantine, H., & Johnson, M. W. (2025). Prolonged adverse effects from repeated psilocybin use in an underground psychedelic therapy training program: a case report. BMC Psychiatry, 25(1), 1-7. (source)
6.Massachusetts General Hospital. (2025). Cardiovascular Effects and Safety of Classic Psychedelics. Advances in Cardiovascular Disease. (source)
7.IsHak, W. W., et al. (2023). The Impact of Psilocybin on Patients Experiencing Psychiatric Symptoms. PMC. (source)
8.Dodd, S., et al. (2023). Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy. CNS Spectrums, 28(5), 534-543. (source)
9.Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020). Long-term effects of psychedelic drugs: A systematic review. Neuroscience & Biobehavioral Reviews, 113, 179-189. (source)
10.Barrett, F. S., et al. (2020). Emotions and brain function are altered up to one month after a single high dose of psilocybin. Scientific Reports, 10(1), 2231. (source)
11.Bremler, R., Katati, N., Shergill, P., Erritzoe, D., & Carhart-Harris, R. L. (2023). Case analysis of long-term negative psychological responses to psychedelics. Scientific Reports, 13(1), 15998. (source)
12.Simonsson, O., et al. (2025). Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms. PMC. (source)
13.Perna, J., et al. (2025). Prolonged adverse effects from repeated psilocybin use in an underground psychedelic therapy training program: a case report. BMC Psychiatry. (source)
14.Meshkat, S., et al. (2024). Impact of psilocybin on cognitive function: A systematic review. PMC. (source)
15.Raison, C. L., et al. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA. (source)
16.Griffiths, R. R., et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology. (source)
17.Sabé, M., et al. (2025). Reconsidering evidence for psychedelic-induced psychosis. Nature. (source)
18.Morris, S. L., et al. (2024). A Case Report of Psilocybin-induced Psychosis in a Vulnerable Individual. PMC. (source)
19.ICES. (2024). Psychedelic use linked to increased risk of schizophrenia study finds. ICES. (source)
20.Honk, L., et al. (2024). Longitudinal associations between psychedelic use and psychotic symptoms. ScienceDirect. (source)
21.Downey, A. E., et al. (2024). Should People with a Family History of Bipolar Disorder Be Excluded from Clinical Trials of Psilocybin Therapy?. PMC. (source)
22.Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., & Kelmendi, B. (2023). Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA, 330(9), 843-853. (source)
23.Williams, M. L., et al. (2025). Eligibility for psychedelic therapy: Clinical trial medical exclusion criteria. ScienceDirect. (source)
24.UCSF Psychedelics. Medical Contraindications to “Classic” Psychedelic Use. UCSF. (source)
25.Psychiatrist.com. (2024). Medical Uses and Adverse Effects of Psilocybin. Psychiatrist.com. (source)
26.Wsół, A., et al. (2023). Cardiovascular safety of psychedelic medicine. PMC. (source)
27.Straumann, I., et al. (2024). Safety pharmacology of acute psilocybin administration. ScienceDirect. (source)
28.Neumann, J., et al. (2024). Effects of hallucinogenic drugs on the human heart. Frontiers in Pharmacology. (source)
29.Cheng, M., et al. (2025). Effects of LSD and Psilocybin on Heart Rate in Patients. MDPI. (source)
30.Cleveland Clinic. (2025). Hypertensive Crisis Linked to Psilocybin Mushroom Use in Patient Taking MAOI and Amphetamine. Cleveland Clinic. (source)
31.Johnson, M. W., Sewell, R. A., & Griffiths, R. R. (2012). Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug and alcohol dependence, 123(1-3), 132-140. (source)
32.NCCIH. Psilocybin for Mental Health and Addiction: What You Need to Know. NCCIH. (source)
33.Health Canada. (2025). Psilocybin and psilocin (Magic mushrooms). Health Canada. (source)
34.Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of psychopharmacology, 30(12), 1268-1278. (source)
35.Gashi, L., Sandberg, S., & Pedersen, W. (2021). Making “bad trips” good: How users of psychedelics narrativize challenging experiences. International Journal of Drug Policy, 87, 102998. (source)
36.Evans, J., et al. (2023). Extended difficulties following the use of psychedelic drugs. PMC. (source)
37.Kopra, E. I., et al. (2022). Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms. Journal of Psychopharmacology. (source)
38.Wood, M. J., et al. (2024). Strategies for resolving challenging psychedelic experiences. Nature. (source)
39.Harari, R., et al. (2024). Psilocybin induces acute anxiety and changes. ScienceDirect. (source)
40.Statharakos, N., et al. (2025). From “bad trips” to “transformative and potentially therapeutic”. PMC. (source)
41.California Poison Control. Magic Mushrooms (Psilocybin) Safety. California Poison Control. (source)
42.Johns Hopkins Hub. (2017). Study explores the enduring positive, negative effects of psilocybin mushrooms. JHU Hub. (source)
Educational Disclaimer
This article is for educational purposes only and does not constitute medical, psychological, or legal advice. The information presented is a summary of findings from scientific research and is not intended to be a comprehensive guide to the use of psychedelic substances. The discussion of risks and side effects does not imply that any use of these substances is safe or appropriate. Individuals with any health concerns or questions should consult with a qualified medical professional. Self-administering psychedelic substances can carry significant health risks, including those detailed in this article. It is illegal to possess, use, or distribute psilocybin in many jurisdictions.